Cathay International Holdings Ld Change of Company Secretary (9920B)

TIDMCTI

RNS Number : 9920B

Cathay International Holdings Ld

12 June 2019

Cathay International Holdings Limited

("Cathay" or the "Company")

Change of Company Secretary

Hong Kong, 12 June 2019 - Cathay International Holdings Limited (LSE: CTI.L), today announces the appointment of Mr. Yiu Chi Hung as Company Secretary with effect from 13 June 2019, having previously served as Company Secretary at Lansen Pharmaceutical Holdings Limited, Cathay's Hong Kong listed subsidiary. His predecessor, Ms. Yip Pui Ling Rebecca, has stepped down from the role with effect from 13 June 2019.

Mr. Yiu graduated with a bachelor degree of Business Administration in Accounting and Finance from the University of Hong Kong in 2013, and he qualified as a member of Hong Kong Institute of Certified Public Accountants. He joined Lansen Pharmaceutical Holdings Limited, a Hong Kong listed subsidiary of Cathay, in 2018 as the Company Secretary and he has demonstrated strong in-house working experience in the company secretarial work, corporate governance and compliance matters.

- ENDS -

For further enquiries, please contact:

 
 Cathay International Holdings Limited 
  Eric Siu (Finance Director)                Tel: [phone] 
  Patrick Sung (Director and Controller) 
 Consilium Strategic Communications 
  Mary-Jane Elliott / Matthew Neal /         Tel: [phone] 
  Lindsey Neville 
 

About Cathay

Cathay International Holdings Limited (LSE: CTI.L) is a main market listed investment holding company and an operator and investor in the healthcare sector in the People's Republic of China (the "PRC"). The Company and its subsidiaries (collectively the "Group") aim to leverage on investment opportunities in the growing domestic demand for high quality healthcare products in the PRC and build portfolio companies into market sector leaders with competitive edge. Cathay has already demonstrated a track record of identifying investment opportunities in this area including: Lansen, a PRC specialty pharmaceutical company focused on rheumatology and dermatology; Haizi, a PRC inositol manufacturer; Natural Dailyhealth, a company engaged in production and sales of plant extracts for use as key active ingredients in healthcare products; and Botai, a company engaged in collagen products.

The Group employs approximately 1,500 people across the PRC, including over 20 specialist corporate and business development staff based at the holding company's offices in Hong Kong and Shenzhen. Cathay also has a hotel investment. For more information please visit the Company's website: www.cathay-intl.com.hk.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [e-mail] or visit www.rns.com.

END

COSBLLFFKQFEBBV

(END) Dow Jones Newswires

June 12, 2019 07:02 ET (11:02 GMT)